🧠 Bipolar Depression Treatment Simulator

Bipolar Depression Presentation

Patient presents in a depressive episode within bipolar disorder.

• Depressive: Episode Polarity (placeholder metric)
• ≥1: Prior Manic Episodes (placeholder metric)
• ~40%: Misdiagnosis Rate (placeholder metric)
• MDQ: Screening Tool (placeholder metric)

Clinical picture

Low mood, anergia and anhedonia dominate the presentation.

Diagnostic caution

Ruling out unipolar depression guides safer drug choice.

Placeholder: unrecognized bipolarity raises switch risk later.

Baseline severity

Severity score anchors the mood dial before treatment.

Quetiapine / Lurasidone / Lamotrigine

Approved agents move mood toward euthymia without antidepressant risk.

• 300 mg: Quetiapine XR (placeholder dose)
• 20–120 mg: Lurasidone (placeholder dose)
• 200 mg: Lamotrigine (placeholder target)
• Low: Switch Risk (placeholder metric)

Mechanism

Each agent stabilizes mood via distinct receptor pathways.

Titration

Slow titration limits sedation and metabolic side effects.

Placeholder: these agents carry no antidepressant-induced switch signal.

Response timeline

Improvement builds gradually over several weeks.

Antidepressant Monotherapy Risk

An antidepressant given alone can destabilize bipolar mood.

• High: Switch Risk (AD alone) (placeholder metric)
• No: Stabilizer Present (placeholder flag)
• Class-wide: Guideline Warning (placeholder metric)
• Weeks 2–6: Onset of Risk (placeholder window)

Why monotherapy is risky

Unopposed antidepressant activity can push mood upward sharply.

Guideline stance

Major guidelines advise against AD monotherapy in bipolar disorder.

Placeholder: risk climbs the longer monotherapy continues.

Warning signs

Irritability and racing thoughts may signal early switch.

Switch-to-Mania Risk Visualization

The dial crosses euthymia and spikes into the manic zone.

• >80%: Peak Switch Risk (placeholder metric)
• Manic pole: Mood Overshoot (placeholder metric)
• Partial: Reversibility (placeholder metric)
• Elevated: Hospitalization Risk (placeholder metric)

The switch mechanism

Antidepressant drive overshoots mood past the stable zone.

Clinical consequence

A manic switch can require urgent dose adjustment.

Placeholder: switch risk scales sharply with treatment weeks.

Recognizing it early

Rapid mood elevation flags a treatment-emergent switch.

Safe Combination Strategy

A mood stabilizer shields against antidepressant-driven switch.

• AD + Stabilizer: Combination Approach (placeholder metric)
• Reduced: Switch Risk (combo) (placeholder metric)
• Quetiapine/Lamotrigine: Preferred Base Agents (placeholder metric)
• Weekly: Monitoring Interval (placeholder metric)

Combination rationale

Stabilizer coverage offsets antidepressant destabilization.

Practical protocol

Stabilizer is established before any antidepressant is added.

Placeholder: combination therapy keeps the dial near euthymia.

Long-term outlook

Maintenance therapy sustains mood stability over time.